# Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor

> **NCT05523947** · PHASE1,PHASE2 · RECRUITING · sponsor: **Yuhan Corporation** · enrollment: 147 (estimated)

## Conditions studied

- HER2-Positive Solid Tumor

## Interventions

- **DRUG:** YH32367

## Key facts

- **NCT ID:** NCT05523947
- **Lead sponsor:** Yuhan Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-08-26
- **Primary completion:** 2028-03-31
- **Final completion:** 2028-04-30
- **Target enrollment:** 147 (ESTIMATED)
- **Last updated:** 2026-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05523947

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05523947, "Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05523947. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*